Εμφανίζονται 1 - 3 Αποτελέσματα από 3 για την αναζήτηση '"нейтрофильно-лимфоцитраный индекс"', χρόνος αναζήτησης: 0,54δλ Περιορισμός αποτελεσμάτων
  1. 1
    Academic Journal

    Πηγή: Malignant tumours; Том 10, № 4 (2020); 5-15 ; Злокачественные опухоли; Том 10, № 4 (2020); 5-15 ; 2587-6813 ; 2224-5057

    Περιγραφή αρχείου: application/pdf

    Relation: https://www.malignanttumors.org/jour/article/view/823/577; Бережная Н. М. Взаимодействие клеток системы иммунитета с другими компонентами микроокружения. Онкология. 2009; 1 (2): 86–93.; Mantovani A. et al. Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 2008; 371 (9614): 771–83.; Тупицын Н. Н. Иммунофенотип рака молочнойжелезы. В кн.: Рак молочнойжелезы. Под ред. Н. Е. Кушлинского, С.М. Портного, К. П. Лактионова. М.: Издательство РАМН, 2005; с. 174–97.; Balch C., Riley L., Bae T. et al. Patterns of human tumor infiltrating lymphocytes in 120 human cancers. Arch Surg 1990; 125 (2): 200–5.; Galon J., Pages F. et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012; 10: 205.; Zamarron B. F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011; 7 (5): 651–658.; Ruffell B., DeNardo D. G., Affara N. I. et al. Lymphocytes in cancer development: polarization towards protumor immunity. Cytokine Growth Factor Rev. 2010; 21: 3–10.; Shen Z. Zhou S., Wang Y. et al. Higher intratumoral infiltrated Foxp3 + Treg numbers and Foxp3 + / C8 + ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin. Oncol. 2010; 136:1585–1595.; Mori M., Shuto K., Kosugi C. et al. An increase in the neutrophil to lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer. 2018;18 (1):1261.; Passardi A., Scarpi E., Cavanna L. et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 2016;7 (22):33210–9. DOI:10.18632 / oncotarget. 8901.; Gunaldi M., Goksu S., Erdem D. et al. Prognostic impact of platelet / lymphocyte and neutrophil / lymphocyte ratios in patients with gastric cancer: a multicenter study. Int J Clin Exp Med. 2015;8 (4):5937–42.; Zheng X., Song X., Shao Y. et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A meta-analysis. Oncotarget. 2017; 8. 10.18632 / oncotarget. 18065.; Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513: 202–209.; Müller P., Rothschild S. I., Arnold W. et al. Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells. Cancer Immunol Immunother 2016; 65: 1–1.; Kollmann D., Ignatova D., Jedamzik J. et al. Expression of programmed cell death protein 1 by tumor-infiltrating lymphocytes and tumor cells is associated with advanced tumor stage in patients with esophageal adenocarcinoma. Ann Surg Oncol 2017; 24: 2698–706.; Huszno J., Nożyńska E. Z., Lange D. et al. The association of tumor lymphocyte infiltration with clinicopathological factors and survival in breast cancer. Pol J Pathol 2017; 68: 26–32.; Lu J., Xu Y., Wu Y. et al. Tumor-infiltrating CD8 + T cells combined with tumor-associated CD68 + macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer. BMC Cancer 2019; 920 (19).; Ebihara T., Sakai N., Koyama S. Suppression by sorted CD8 + CD11b-cells from T-cell growth factor-activated peripheral blood lymphocytes on cytolytic activity against tumor in patients with gastric carcinoma. Eur J of Cancer 1991; 27 (12): 1654–7 / 19. Hou J., Yu Z., Xiang R. et al. Correlation between infiltration of FOXP3 + regulatory T cells and expression of B7-H1 in the tumor tissues of gastric cancer. Exp Molecular Pathol 2014; 96 (3): 284–91.; Yuan X. L., Chen L., Li M-X. et al. Elevated expression of Foxp3 in tumor-infiltrating Treg cells suppresses T-cell proliferation and contributes to gastric cancer progression in a COX - 2-dependent manner. Clin Immunol 2010; 134 (3): 277–88.; Peng L. S., Mao F. Y., Zhao Y. L. et al. Altered phenotypic and functional characteristics of CD3 + CD56 + NKT-like cells in human gastric cancer. Oncotarget 2016; 7 (34): 55222–30. DOI:10.18632 / oncotarget. 10484; Takeuchi H., Maehara Y., Tokunaga E. et al. Prognostic Significance of Natural Killer Cell Activity in Patients With Gastric Carcinoma: A Multivariate Analysis. Am J Gastroenterol 2001; 96 (2): 574–8.; https://www.malignanttumors.org/jour/article/view/823

  2. 2
  3. 3
    Academic Journal

    Πηγή: Advances in Molecular Oncology; Том 7, № 1 (2020); 38-46 ; Успехи молекулярной онкологии; Том 7, № 1 (2020); 38-46 ; 2413-3787 ; 2313-805X ; 10.17650/2313-805X-2020-7-1

    Περιγραφή αρχείου: application/pdf

    Relation: https://umo.abvpress.ru/jour/article/view/256/200; Global Burden of Disease Cancer Collaboration, Fitzmaurice C., Allen C. et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3(4):524–48. DOI:10.1001/jamaoncol.2016.5688.; Давыдов М.И., Аксель Е.М. Заболеваемость злокачественными новообразованиями населения России и стран СНГ в 2004 г. Вестник РОНЦ им. Н.Н. Блохина РАМН 2008; 19(2 прил.1):52–90.; Давыдов М.И., Тер Ованесов М.В. Современная стратегия хирургического лечения рака желудка. Современная онкология 2000;2(1):4–10.; Yazici O., Sendur M.A., Ozdemir N., Aksoy S. Targeted therapies in gastric cancer and future perspectives. World J Gastroenterol 2016;22(2):471–89. DOI:10.3748/wjg.v22.i2.471.; Waddell T., Verheij M., Allum W. et al. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24 Suppl 6:vi57–63. DOI:10.1093/annonc/mdt344.; Okines A.F., Norman A.R., McCloud P. et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabinebased combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol 2009;20(9):1529–34. DOI:10.1093/annonc/mdp047.; Бережная Н.М. Взаимодействие клеток системы иммунитета с другими компонентами микроокружения. Онкология 2009;1(2):86–93.; Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002;420(6917):860–7. DOI:10.1038/nature01322.; Takenaka Y., Oya R., Kitamiura T. et al. Platelet count and platelet-lymphocyte ratio as prognostic markers for head and neck squamous cell carcinoma: Metaanalysis. Head Neck 2018;40(12): 2714–23. DOI:10.1002/hed.25366.; Mori M., Shuto K., Kosugi C. et al. An increase in the neutrophil-tolymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer. BMC Cancer 2018;18(1):1261. DOI:10.1186/s12885-018-5171-2.; Galon J., Pages F., Marincola F.M. et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012;10:205. DOI:10.1186/1479-5876-10-205.; Passardi A., Scarpi E., Cavanna L. et al. Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer. Oncotarget 2016;7(22):33210–9. DOI:10.18632/oncotarget.8901.; Gunaldi M., Goksu S., Erdem D. et al. Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study. Int J Clin Exp Med 2015;8(4):5937–42.; Кутукова С.И., Беляк Н.П., Раскин Г.А. и др. Cистемное воспаление и иммунологическое микроокружение в прогнозе течения солидных опухолей. Злокачественные опухоли 2019;9(1):29–37. DOI:10.18027/2224-5057-2019-9-1-29-37.; Desbois M., Rusakiewicz S., Locher C. et al. Natural killer cells in non-hemato-poietic malignancies. Front Immunol 2012;3:395. DOI:10.3389/fimmu.2012.00395.; Liu G.O., Song-Wen H., Ke P. Prognostic significance of preoperative CD8+ central memory T cells for operable and advanced gastric cancer Int J Clin Exp Pathol 2017;10(3):3424–30.; Mantovani A., Romero P., Palucka A.K., Marincola F.M. Tumor immunity: effector response to tumor and role of the microenvironment. Lanset 2008;371(9614): 771–83. DOI:10.1016/S0140-6736(08)60241-X.; Тупицын Н.Н. Иммунофенотип рака молочной железы. В кн.: Рак молочной железы. Под ред. Н.Е. Кушлинского, С.М. Портного, К.Г. Лактионова. М.: РАМН, 2005. С. 174–197.; https://umo.abvpress.ru/jour/article/view/256